| Title |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, December 2009
|
| DOI | 10.1007/s00280-009-1170-y |
| Pubmed ID | |
| Authors |
Brett E. Houk, Carlo L. Bello, Bill Poland, Lee S. Rosen, George D. Demetri, Robert J. Motzer |
| Abstract |
In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (mRCC). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Australia | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 172 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| United States | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 168 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 43 | 25% |
| Researcher | 35 | 20% |
| Other | 25 | 15% |
| Student > Bachelor | 11 | 6% |
| Student > Master | 8 | 5% |
| Other | 21 | 12% |
| Unknown | 29 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 75 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 11% |
| Agricultural and Biological Sciences | 15 | 9% |
| Mathematics | 5 | 3% |
| Biochemistry, Genetics and Molecular Biology | 4 | 2% |
| Other | 18 | 10% |
| Unknown | 36 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2016.
All research outputs
#7,347,142
of 25,390,970 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#629
of 2,560 outputs
Outputs of similar age
#42,413
of 174,374 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#7
of 19 outputs
Altmetric has tracked 25,390,970 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,560 research outputs from this source. They receive a mean Attention Score of 4.5. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.